LAA OCCLUDER
STRUCTURAL INTERVENTIONS
Designed to treat patients with non-valvular atrial fibrillation (AF), who are at risk of ischemic stroke, the Amplatzer™ Amulet™ LAA Occluder offers complete closure of the left atrial appendage (LAA) and immediately eliminates the need for oral anticoagulants (OACs).1
SWITCH TO THE REFERRAL VIEW For more information specific to neurology regarding LAA Occlusion
STROKE RISK REDUCTION AND FREEDOM FROM ANTICOAGULANTS
Clinical studies have shown that implanting AF patients with the Amplatzer™ Amulet™ Occluder is a safe and effective treatment option to reduce their risk of stroke and eliminate the need for oral anticoagulants.

Success
Rate2

Effective
Closure1

Left the hospital
without using OACs1

Reduction
in Stroke Risk2
FIND OUT MORE ABOUT AMULET™ OCCLUDER DATA:
SEE AMULET™ IDE 3 YR DATA SEE AMULET™ IDE 5 YR DATA SEE OBSERVATIONAL STUDY
THE AMULET OCCLUDER IS PROVEN TO PROVIDE SUPERIOR COMPLETE CLOSURE1. Head-To-Head study demonstrates 63% lower risk of moderate or greater leaks with Amulet occluder3
Amulet occluder patients had significantly higher complete LAA closure rate by TEE compared to Watchman‡ device at both 45 days and 12 months.
TV
TV
- Lakkireddy D, Thaler D, Ellis CR, et al. Amplatzer™ Amulet™ Left Atrial Appendage Occluder versus Watchman™ device for stroke prophylaxis (Amulet IDE): A randomized, controlled trial. Circulation. 2021; 144(19) :1543–1552. doi.org/10.1161/CIRCULATIONAHA.121.057063.
- Hildick-Smith D, Landmesser U, Camm AJ, et al. Left atrial appendage occlusion with the Amplatzer™ Amulet™ device: full results of the prospective global observational study. Eur Heart J. 2020; 41(30):2894–2901. doi.org/10.1093/eurheartj/ehaa169.
- Ellis et al. HRS 2022.